title: Eosinophilic fasciitis occurring under treatment with natalizumab for multiple sclerosis.
abstract: BACKGROUND
  Eosinophilic fasciitis is a rare sclerosing syndrome with a poorly understood etiology.
  
  
  OBJECTIVE
  We report a case of eosinophilic fasciitis in a 40-year-old man undergoing treatment with natalizumab for multiple sclerosis. Natalizumab is a selective adhesion molecule inhibitor that prevents interaction of leukocytes with endothelial cells. Peripheral blood eosinophilia has been described under treatment with natalizumab, but we herein report the first case to our knowledge of eosinophilic fasciitis as a possible complication of this medication.
authors.forename: Janie
authors.initials: J
authors.lastname: Bujold
authors.forename: Catherine
authors.initials: C
authors.lastname: Boivin
authors.forename: Mohamed
authors.initials: M
authors.lastname: Amin
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bouchard
authors.forename: Jacques
authors.initials: J
authors.lastname: Soucy
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D004802:Eosinophilia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D005208:Fasciitis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D006886:Hydroxychloroquine